147
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Fibrinolysis Therapy Combined with Deferred PCI versus Primary Angioplasty for STEMI Patients During the COVID-19 Pandemic: Preliminary Results from a Single Center

ORCID Icon, , , &
Pages 201-209 | Published online: 19 Jan 2021

References

  • Cucinotta D, Vanelli M. WHO declares COVID-19 a Pandemic. Acta Biomed. 2020;91(1):157–160. doi:10.23750/abm.v91i1.9397
  • Abdi S, Salarifar M, Mortazavi SH, et al. COVID-19 sends STEMI to quarantine!? Clin Res Cardiol. 2020;1–2.
  • De Rosa S, Spaccarotella C, Basso C, et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020;41(22):2083–2088. doi:10.1093/eurheartj/ehaa409
  • Masroor S. Collateral damage of COVID-19 pandemic: delayed medical care. J Card Surg. 2020;35(6):1345–1347. doi:10.1111/jocs.14638
  • Garcia S, Albaghdadi MS, Meraj PM, et al. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol. 2020;75(22):S0735–1097. doi:10.1016/j.jacc.2020.04.011
  • Tam CF, Cheung KS, Lam S, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on outcome of myocardial infarction in Hong Kong, China. Catheter Cardiovasc Interv. 2020. doi:10.1002/ccd.28943
  • Ibanez B, James S, Agewall S, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;2018(39):119‐77.
  • Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-Elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-Elevation myocardial infarction. J Am Coll Cardiol. 2016;67(10):1235–1250. doi:10.1016/j.jacc.2015.10.005
  • Han Y, Zeng H, Jiang H, et al. CSC expert consensus on principles of clinical management of patients with severe emergent cardiovascular diseases during the COVID-19 epidemic. Circulation. 2020;141(20):e810‐6. doi:10.1161/CIRCULATIONAHA.120.047011
  • Rashid MK, Guron N, Bernick J, et al. Safety and efficacy of a pharmacoinvasive strategy in st-segment elevation myocardial infarction: a patient population study comparing a pharmacoinvasive strategy with a primary percutaneous coronary intervention strategy within a regional system. JACC Cardiovasc Interv. 2016;9(19):2014–2020. doi:10.1016/j.jcin.2016.07.004
  • Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379–1387. doi:10.1056/NEJMoa1301092
  • Sinnaeve PR, Armstrong PW, Gershlick AH, et al. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: strategic reperfusion early after myocardial infarction (STREAM) 1-year mortality follow-up. Circulation. 2014;130(14):1139–1145. doi:10.1161/CIRCULATIONAHA.114.009570
  • Shuvy M, Beeri G, Klein E, et al. Accuracy of the Global Registry of Acute Coronary Events (GRACE) risk score in contemporary treatment of patients with acute coronary syndrome. Can J Cardiol. 2018;34(12):1613–1617. doi:10.1016/j.cjca.2018.09.015
  • Williams BA, Chagin KM, Bash LD, et al. External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. Atherosclerosis. 2018;272:80–86. doi:10.1016/j.atherosclerosis.2018.03.026
  • Bundhun PK, Sookharee Y, Bholee A, Huang F. Application of the SYNTAX score in interventional cardiology: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(28):e7410. doi:10.1097/MD.0000000000007410
  • Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–2351. doi:10.1161/CIRCULATIONAHA.106.685313
  • Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People’s Hospital. Intensive Care Med. 2020;46(6):1111–1113. doi:10.1007/s00134-020-05993-9
  • Kirtane AJ, Bangalore S. Why fibrinolytic therapy for ST-segment-elevation myocardial infarction in the COVID-19 pandemic is not your new best friend. Circ Cardiovasc Qual Outcomes. 2020;13(6):e006885. doi:10.1161/CIRCOUTCOMES.120.006885
  • Mahmud E, Dauerman HL, Welt FGP, et al. Management of acute myocardial infarction during the COVID-19 pandemic: a consensus statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). Catheter Cardiovasc Interv. 2020. doi:10.1002/ccd.28946
  • Roffi M, Guagliumi G, Ibanez B. The obstacle course of reperfusion for STEMI in the COVID-19 pandemics. Circulation. 2020;141(24):1951–1953. doi:10.1161/CIRCULATIONAHA.120.047523
  • Ferlini M, Andreassi A, Carugo S, et al. Centralization of the ST elevation myocardial infarction care network in the Lombardy region during the COVID-19 outbreak. Int J Cardiol. 2020;312:24–26. doi:10.1016/j.ijcard.2020.04.062
  • Tumminello G, Barbieri L, Lucreziotti S, et al. Impact of COVID-19 on STEMI: second youth for fibrinolysis or time to centralized approach? Int J Cardiol Heart Vasc. 2020;30:100600. doi:10.1016/j.ijcha.2020.100600
  • Tam CF, Cheung KS, Lam S, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020;13(4):e006631. doi:10.1161/CIRCOUTCOMES.120.006631
  • Daniels MJ, Cohen MG, Bavry AA, Kumbhani DJ. Reperfusion of ST-segment-elevation myocardial infarction in the COVID-19 era: business as usual? Circulation. 2020;141(24):1948–1950. doi:10.1161/CIRCULATIONAHA.120.047122
  • Tasar O, Karabay AK, Oduncu V, Kirma C. Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2019;30(4):270–276. doi:10.1097/MCA.0000000000000726
  • Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J. 2016;68(4):539–551. doi:10.1016/j.ihj.2016.04.006
  • Harrison RW, Aggarwal A, Ou FS, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol. 2013;111(2):178–184. doi:10.1016/j.amjcard.2012.09.015
  • Pu J, Ding S, Ge H, et al. Efficacy and safety of a pharmaco-invasive strategy with half-dose alteplase versus primary angioplasty in st-segment-elevation myocardial infarction: EARLY-MYO trial (early routine catheterization after alteplase fibrinolysis versus primary PCI in acute ST-segment-elevation myocardial infarction). Circulation. 2017;136(16):1462–1473. doi:10.1161/CIRCULATIONAHA.117.030582
  • Mahmoud AN, Saad M, Elgendy AY, Mentias A, Elgendy IY. Deferred or immediate stent implantation for primary percutaneous coronary intervention: a meta-analysis of randomized trials. Catheter Cardiovasc Interv. 2018;91(2):260–264. doi:10.1002/ccd.27240
  • Danchin N, Popovic B, Puymirat E, et al. Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme. Eur Heart J. 2020;41(7):858–866. doi:10.1093/eurheartj/ehz665
  • Thrane PG, Kristensen SD, Olesen KKW, et al. 16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction. Eur Heart J. 2020;41(7):847–854. doi:10.1093/eurheartj/ehz595
  • Nielsen PH, Terkelsen CJ, Nielsen TT, et al. System delay and timing of intervention in acute myocardial infarction (from the Danish Acute Myocardial Infarction-2 [DANAMI-2] trial). Am J Cardiol. 2011;108(6):776–781. doi:10.1016/j.amjcard.2011.05.007